3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Completed
37
Terminated
11
Unknown
3
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
57
Breast Neoplasms
52
Leukemia, Myeloid, Acute
40
Carcinoma, Non-Small-Cell Lung
40
Lymphoma
35
Pancreatic Neoplasms
30
Leukemia, Lymphocytic, Chronic, B-Cell
30
Leukemia
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Neoplasm Metastasis
27
Ovarian Neoplasms
25
Multiple Myeloma
25
Lymphoma, Non-Hodgkin
25
Recurrence
24
Lung Neoplasms
23
Melanoma
22
Lymphoma, Large B-Cell, Diffuse
21
Prostatic Neoplasms
20
Glioblastoma
20
Brain Neoplasms
19
Colorectal Neoplasms
18
Lymphoma, Follicular
17
Squamous Cell Carcinoma of Head and Neck
16
Sarcoma
16
Lymphoma, B-Cell
15
Lymphoma, Mantle-Cell
14
Myelodysplastic Syndromes
13
Urinary Bladder Neoplasms
12
Lymphoma, B-Cell, Marginal Zone
12
Glioma
12
Interventions
Idarubicin
1
Cytarabine
1
BI 6727
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Withdrawn
×
Leukemia, Myelomonocytic, Acute
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn